Arcus Q4 2024 net loss $94M; casdatifan shows best-in-class potential in ccRCC

Arcus Biosciences, Inc.

Revenue $36M for Q4 2024 ($31M Q4 2023); net loss widened to $94M from $81M.
Cash & marketable securities $992M as of Dec 31, 2024, up from $866M year-end 2023.
Casdatifan monotherapy in IO/VEGFR-TKI experienced ccRCC achieved 30%+ ORR, 9.7-month median PFS (50mg BID).
Phase 3 PEAK-1 (casdatifan + cabozantinib vs cabo in post-IO ccRCC) expected to initiate Q2 2025.
Domvanalimab/zimberelimab Phase 3 STAR-221 top-line data for 1L upper GI cancers expected 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.